Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

2020394 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 21, Issue 12, pp. 1630-1642

Field-Weighted Citation Impact: 32.60